Search Results
Your search for Matthew matches 8054 pages
Showing 8001 - 8050No Additional Benefit of Double Endocrine Treatment After Progression on Aromatase Inhibitors in Advanced Hormone Receptor–Positive Breast Cancer
In the SoFEA trial, reported in Lancet Oncology by Stephen R.D. Johnston, PhD, FRCP, of Royal Marsden NHS Foundation Trust, and colleagues, postmenopausal women with advanced hormone receptor–positive breast cancer that progressed on nonsteroidal aromatase inhibitors were treated with the...
Lenalidomide plus Dexamethasone Delays Progression and Improves Survival in High-risk Smoldering Multiple Myeloma
In a study reported in The New England Journal of Medicine, María-Victoria Mateos, MD, PhD, of the Universidad de Salamanca, and colleagues compared induction lenalidomide (Revlimid) plus dexamethasone followed by maintenance lenalidomide with observation in patients with high-risk...
Benefit Seen with Both Autologous and Allogeneic Hematopoietic Cell Transplantation in T-cell Non-Hodgkin Lymphoma
In a report in Journal of Clinical Oncology, Sonali M. Smith, MD, of University of Chicago Hospitals, and colleagues analyzed outcomes in a large cohort of autologous or allogeneic hematopoietic cell transplantation recipients with the most common T-cell non-Hodgkin lymphoma histologies. Their ...
Low-dose CT Screening for Lung Cancer: Details of First Round of Screening in National Lung Screening Trial
The National Lung Screening Trial found that 3 years of annual screening with low-dose helical computed tomography (CT) reduced lung cancer mortality compared with chest radiography in older persons who were heavy smokers. The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial also...
Swedish Initiative Results in Significant Reduction in Inappropriate Prostate Cancer Imaging
A number of initiatives have been implemented to encourage reduction of inappropriate use of imaging to stage incident prostate cancer. Since 2000, the National Prostate Cancer Register (NPCR) of Sweden has led an effort to decrease national rates of inappropriate prostate cancer imaging by...
Particulate Matter Air Pollution Contributes to Increased Risk of Lung Cancer in Europe
Ambient air pollution has been associated with lung cancer risk. In a study reported in Lancet Oncology by Ole Raaschou-Nielsen, PhD, of the Danish Cancer Society Research Center, and colleagues, lung cancer incidence in European countries was prospectively assessed according to several measures of ...
No Benefit of Adding Atrasentan to Docetaxel in Advanced Castration-resistant Prostate Cancer
The endothelin pathway has a role in bone metastases, which are characteristic of advanced prostate cancer, and the investigational endothelin receptor antagonist atrasentan has shown activity in prostate cancer. In the SWOG S0421 trial reported in Lancet Oncology by David I. Quinn, FRACP, of...
Docetaxel Superior to Erlotinib in Second-line Treatment of Advanced NSCLC with Wild-type EGFR
There is ongoing debate about the efficacy of erlotinib (Tarceva) in patients with advanced non–small cell lung cancer (NSCLC) whose tumors have wild-type EGFR. In the TAILOR trial, reported in Lancet Oncology by Marina Chiara Garassino, MD and colleagues, erlotinib was compared with standard ...
Study Evaluates Therapeutic Impact of Laparoscopic Para-aortic Staging Surgery before Chemoradiotherapy in Cervical Cancer
In a study reported in Journal of Clinical Oncology, Sebastien Gouy, MD, of Institut Gustave Roussy, and colleagues evaluated survival outcomes in locally advanced cervical cancer patients with negative PET-CT imaging results who underwent laparoscopic para-aortic staging surgery before...
No Difference in Event-free Survival with Chemotherapy before vs after Radiation Therapy in Children with High-risk Medulloblastoma
A number of different strategies for combining chemotherapy and radiation therapy have been evaluated in the effort to improve survival in patients with high-risk medulloblastoma. In a trial (POG 9031) reported in Journal of Clinical Oncology, Nancy J. Tarbell, MD, of Massachusetts General Hospital ...
Molecular Profiling Improves Classification of Nodal Peripheral T-cell Lymphomas
The differential diagnosis of the most common peripheral T-cell lymphoma subtypes is difficult. In a phase III diagnostic accuracy study reported in Journal of Clinical Oncology, Pier Paolo Piccaluga, MD, PhD, of the University of Bologna, and colleagues in the European T-cell Lymphoma Study Group...
National Lung Screening Trial Analysis Supports Risk-based Targeting of Smokers for Low-dose CT Screening
The National Lung Screening Trial (NLST) showed that screening with low-dose computed tomography (CT) resulted in a 20% reduction in lung cancer mortality compared with chest radiography in participants aged 55 to 74 years with a minimum of 30 pack-years of smoking and no more than 15 years since...
Radium-223 Dichloride Prolongs Overall Survival in Men with Metastatic Prostate Cancer in Phase III ALSYMPCA Trial
In a trial (ALSYMPCA) reported in The New England Journal of Medicine, Chris Parker, MD, from Royal Marsden Hospital in Surrey, United Kingdom, and colleagues compared the alpha emitter radium-223 dichloride (Xofigo) with best standard of care in men with castration-resistant prostate cancer and...
Female Survivors of Childhood Cancer Have Increased Risk of Infertility
Decreased pregnancy rates and early menopause have been reported in female cancer survivors, although there is less information on infertility rates and reproductive interventions in these patients. In a study reported in Lancet Oncology, Sara E. Barton, MD, of Brigham and Women’s Hospital...
Adenovirus-mediated Gene Therapy with Sitimagene Ceradenovec Prolongs Median Time to Death or Reintervention in Adult Glioblastoma
In an open-label phase III trial (ASPECT) reported in Lancet Oncology, Manfred Westphal, MD, of University Hospital Eppendorf in Hamburg, and colleagues assessed the effects of locally applied adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir after...
Progesterone and Estrogen Receptor Expression Are Prognostic Markers for Endometrioid and High-grade Serous Ovarian Cancer
Few markers of ovarian cancer prognosis have been established, perhaps because potential subtype associations are missed in studies including patients with all histopathologic subtypes. In a study reported in Lancet Oncology, Weiva Sieh, PhD, of Stanford University and colleagues assessed the...
American Ginseng Improves Cancer-related Fatigue
In a collaborative phase III trial of the North Central Cancer Treatment Group and Mayo Clinic reported in Journal of the National Cancer Institute by Debra L. Barton, RN, PhD, of the Mayo Clinic, and colleagues, patients with cancer-related fatigue were treated with Wisconsin ginseng (a common...
Accelerated Partial-breast Irradiation Using 3D Conformal Radiation Therapy Causes More Adverse Events Compared with Whole-breast Irradiation
The RAPID trial compared accelerated partial-breast irradiation using three-dimensional (3D) conformal external-beam radiation therapy vs whole-breast irradiation in women with invasive or in situ breast cancer ≤ 3 cm. As reported by Ivo A. Olivotto, MD, FRCPC, of the British Columbia Cancer...
Bevacizumab/Pemetrexed Maintenance Increases Progression-free Survival vs Bevacizumab Alone in Advanced Nonsquamous NSCLC
Maintenance therapy is associated with improved survival in non–small cell lung cancer (NSCLC), but few studies have compared active agents in this setting. In a phase III trial (AVAPERL trial) reported in Journal of Clinical Oncology by Fabrice Barlesi, MD, PhD, of Aix Marseille...
Significant Improvement in Overall Survival Seen with Pemetrexed Maintenance after Pemetrexed/Cisplatin Induction in Patients with Advanced NSCLC
In the phase III PARAMOUNT trial, pemetrexed (Alimta) continuation maintenance therapy significantly reduced the risk of disease progression by 38% compared with placebo after pemetrexed/cisplatin induction in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Final...
Obinutuzumab Shows Activity in Relapsed/Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma and Indolent Non-Hodgkin Lymphoma
Obinutuzumab is a type II, glycoengineered, humanized anti-CD20 monoclonal antibody. In the phase II GAUGUIN studies reported in Journal of Clinical Oncology by Franck Andre Morschhauser, MD, PhD of Centre Hospitalier Régional Universitaire de Lille and Gilles A. Salles, MD, PhD, of Hospices ...
Whole-exome Sequencing of the NCI-60 Cell Line Panel Provides a Genomic Resource for Cancer Biology and Systems Pharmacology
The NCI-60 cell lines, which represent cancers of lung, colon, brain, ovary, breast, prostate, and kidney as well as leukemia and melanoma, are the most frequently studied human tumor cell lines in cancer research and have generated the most extensive cancer pharmacology database worldwide. As...
Addition of Aflibercept to Docetaxel/Prednisone Does Not Improve Overall Survival in Men with Metastatic Castration-resistant Prostate Cancer
In a phase III double-blind study (VENICE trial) reported in Lancet Oncology, Ian F. Tannock, DSc, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the addition of the antiangiogenic agent aflibercept (Zaltrap) to standard docetaxel/prednisone therapy in patients with...
Addition of Panitumumab to Cisplatin/Fluorouracil Improves Progression-free Survival in Patients with Recurrent or Metastatic Head and Neck Cancer
Previous studies have shown that anti-EGFR monoclonal antibody treatment can improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In the open-label phase III SPECTRUM trial, Jan B. Vermorken, MD, of Antwerp University Hospital and...
Afatinib Prolongs Progression-free Survival Compared with Cisplatin plus Pemetrexed in EGFR-mutant Advanced Lung Adenocarcinoma
Afatinib is an oral selective ErbB family inhibitor that irreversibly blocks signaling from EGFR/ErbB1, HER2/ErbB2, and ErbB4 and has exhibited broad-spectrum activity against EGFR mutations in preclinical studies. A phase II study of afatinib in EGFR-mutation positive lung adenocarcinoma showed...
Bladder-sparing Trimodal Chemotherapy Produces Good Response in Patients with Muscle-invasive Bladder Cancer
In a phase II study reported in Lancet Oncology, Timur Mitin, MD, of Massachusetts General Hospital, and colleagues assessed the effects of adding paclitaxel or fluorouracil (5-FU) to radiation therapy plus cisplatin followed by adjuvant chemotherapy in a program of selected bladder preservation in ...
High Prediagnosis Red Meat Consumption Associated with Increased All-cause Mortality in Patients with Colorectal Cancer
There is evidence that diets high in red and processed meat are associated with increased risk of colorectal cancer. In a study reported in Journal of Clinical Oncology, Marjorie L. McCullough, ScD, and colleagues from the Epidemiology Research Program of the American Cancer Society examined the...
Volumetric Growth Rate of Small Colorectal Polyps on CT Colonography May Be Useful Risk Marker
The growth rates and clinical importance of small colorectal polyps have not been well established. In a study reported in Lancet Oncology, Perry J. Pickhardt, MD, of the University of Wisconsin School of Medicine and Public Health, and colleagues found that volumetric growth rate on computed...
Height Differences May Explain Excess Cancer Risk for Men
Most cancers occur more frequently in men than in women and greater height has been associated with increased risk for some cancers. In a study reported in Journal of the National Cancer Institute, Roland B. Walter, MD, PhD, of the Fred Hutchinson Cancer Research Center, and colleagues found that...
L1CAM Predicts Recurrence and Poor Outcome in Early-stage Type I Endometrial Cancer
Although patients with early-stage type I endometrial cancer have very good prognosis, a substantial proportion experience recurrence and die from the disease. In a study published in Journal of the National Cancer Institute, Alain G. Zeimet, MD, PhD, of Innsbruck Medical University, Austria, and...
Intercalated Chemotherapy plus Erlotinib Improves Survival in Asian Patients with Advanced NSCLC and Known or Unknown EGFR Mutation Status
In a phase III trial (FASTACT-2) conducted in 28 centers in seven Asian countries, Yi-Long Wu, MD, of the Guangdong Academy of Medical Sciences and colleagues found that the intercalated combination of erlotinib (Tarceva) and chemotherapy improved progression-free survival vs chemotherapy alone as...
Acupuncture May Reduce Arm Lymphedema in Patients with Breast Cancer
Arm lymphedema affects approximately 30% of breast cancer survivors, with rates increasing with longer follow-up and cases presenting well beyond the active treatment period. Lymphedema is observed even with use of less-invasive surgical techniques for staging, and risk is further increased by such ...
Crizotinib Improves Progression-free Survival vs Pemetrexed or Docetaxel in Advanced ALK-positive NSCLC
In a phase III trial reported by Alice T. Shaw, MD, PhD, of Massachusetts General Hospital, and colleagues in The New England Journal of Medicine, crizotinib (Xalkori) improved progression-free survival compared with standard chemotherapy in previously treated patients with advanced...
Lugano 2013: BCL2 Overexpression and Non–Germinal Center B-cell–like Subtype Predict Poorer Survival in Diffuse Large B-cell Lymphoma
In studies to identify prognostic factors in diffuse large B-cell lymphomas, Thierry J. Molina, MD, PhD, of Paris Descartes University, and colleagues assessed expression of MYC, BCL2, MYC/BCL2, IgM, and germinal center B-cell–like and non–germinal center B-cell–like subtypes in a ...
Majority of Patients with Incurable Lung Cancer Have Inaccurate Expectations about Goals of Radiation Therapy
Aileen B. Chen, MD, MPP, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, and colleagues in the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium recently assessed patient expectations regarding goals of radiation therapy (RT) for incurable lung cancer. They ...
Study Reveals Abstracts with Financial Conflicts of Interest Have Higher Meeting Prominence, Better Peer Review Score
Beverly Moy, MD, Clinical Director of the Breast Oncology Program at Massachusetts General Hospital, and colleagues recently analyzed the relationship between declaration of financial conflicts of interest and "research prominence" for abstracts presented at American Society of Clinical Oncology...
Lugano 2013: Vitamin D Deficiency Associated with Worse Outcome in Elderly Patients with Aggressive B-cell Lymphoma Receiving R-CHOP or CHOP
Vitamin D deficiency recently was shown to be associated with worse outcome in patients with non-Hodgkin lymphoma. To determine whether such an association exists in patients with aggressive B-cell lymphoma, Jörg T. Bittenbring, of Saarland University Medical School, Germany, and colleagues in ...
Lugano 2013: Chlorambucil plus Rituximab Produces Better Event-free and Progression-free Survival in Extranodal Marginal Zone B-cell Lymphoma
The International Extranodal Lymphoma Study Group (IELSG)-19 trial is the largest randomized trial in extranodal marginal zone B-cell lymphoma conducted to date. As reported by Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland, and colleagues, preliminary final results of the...
Lugano 2013: PET-guided Radiation Therapy Improves Survival in Patients with Advanced Diffuse Large B-cell Lymphoma
Residual masses are often detected on post-therapy computed tomography (CT) scans in patients with diffuse large B-cell lymphoma, and the potential role of consolidative radiation therapy in such cases remains undefined. An analysis of the use of PET-guided radiation therapy presented by Laurie H....
Lugano 2013: Ibrutinib Highly Active in Patients with Chronic Lymphocytic Leukemia with 17p Deletion
The 17p deletion in chronic lymphocytic leukemia (CLL) is associated with worse outcome in patients receiving standard chemotherapy. The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown durable antitumor activity in high-risk CLL. Adrian Wiestner, MD, PhD, of the National...
Chemotherapy-induced Neuropathy Has Long-term Effect on Colorectal Cancer Survivors
In a study reported in Journal of Clinical Oncology, Floortje Mols, PhD, of the Center of Research on Psychology in Somatic Diseases, Tilburg University, and colleagues assessed the prevalence and severity of chemotherapy-induced neuropathy and its affect on health-related quality of life in...
BTK Inhibitor Ibrutinib Produces High Response Rate in Relapsed/Refractory Mantle Cell Lymphoma
Ibrutinib is a first-in-class oral covalent inhibitor of Bruton’s tyrosine kinase (BTK), a mediator of the B-cell receptor signaling pathway implicated in the pathogenesis of B-cell cancers. As reported in The New England Journal of Medicine, Michael L. Wang, MD, of The University...
High Rate of Durable Remissions with BTK Inhibitor Ibrutinib in Patients with Relapsed Chronic Lymphocytic Leukemia
Durable remissions are uncommon with current treatments for relapsed chronic lymphocytic leukemia (CLL). Bruton’s tyrosine kinase (BTK) is an essential component of B-cell receptor signaling that mediates interactions with the tumor microenvironment and promotes survival and proliferation of...
Follicular Lymphoma Cells Induce Changes in T-cell Gene Expression and Function, Show Prognostic Significance for Survival
It has been shown that CD4 and CD8 tumor-infiltrating lymphocytes in follicular lymphoma have impaired function and suppressed recruitment of critical signaling proteins to the immunologic synapse, and a number of studies have indicated the prognostic importance of the immune microenvironment in...
First-line Carboplatin plus Pemetrexed Improves Survival vs Pemetrexed Alone in Patients with Advanced NSCLC and Poor Performance Status
A significant proportion of patients with advanced non–small cell lung cancer (NSCLC) have poor performance status, and optimal clinical management of these patients has not been established. In an attempt to help define optimal chemotherapy in such patients, Mauro Zukin, MD, of Instituto...
Imatinib Active in Melanomas with KIT Mutation but Not KIT Amplification Alone
Mutations and amplifications in the KIT oncogene have been identified in mucosal and acral melanomas and in melanomas arising on chronically sun-damaged skin. In a multicenter phase II study reported in the Journal of Clinical Oncology, F. Stephen Hodi, MD, of Dana-Farber Cancer Institute, and...
Novel Selective ALK Inhibitor Demonstrates Good Activity in Advanced NSCLC
Crizotinib (Xalkori), a multitargeted receptor tyrosine kinase inhibitor, is the only agent currently available for treating ALK-rearranged non–small cell lung cancer (NSCLC). CH5424802 is a novel selective oral ALK inhibitor with activity in tumor cell lines harboring ALK alterations,...
PHARE Trial Fails to Establish Noninferiority of 6 vs 12 Months of Adjuvant Trastuzumab in Early HER2-positive Breast Cancer
The phase III open-label PHARE trial, conducted in 156 centers in France, examined whether 6 months of adjuvant trastuzumab (Herceptin) was noninferior to 12 months of treatment in women with early HER2-positive breast cancer. As reported by Xavier Pivot, MD, of University Hospital Jean-Minjoz,...
Impact of Age on Efficacy of Newer Adjuvant Therapies in Patients with Stage II/III Colon Cancer
Available data suggest that patients with stage II/III colon cancer receive similar benefit from intravenous fluorouracil (5-FU) adjuvant therapy regardless of age. Combination regimens and oral fluoropyrimidine therapy are now standard treatments in this setting. Nadine J. McCleary, MD, MPH, and...
Acetyl-L-carnitine Ineffective for Taxane-related Peripheral Neuropathy
Various studies have suggested that acetyl-L-carnitine, a natural compound involved in neuronal protection, may be effective in preventing and treating sensory neuropathy. Dawn L. Hershman, MD, MS, of Columbia University Medical Center, and colleagues recently assessed whether daily...
